IONS - Ionis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Ionis Pharmaceuticals, Inc.

2855 Gazelle Court
Carlsbad, CA 92010
United States
760 931 9200

Full Time Employees796

Key Executives

NameTitlePayExercisedYear Born
Dr. Brett P. Monia Ph.D.Founder, CEO & Director1.71MN/A1961
Ms. Elizabeth L. Hougen M.A., M.B.A., M.S.Exec. VP of Fin. & CFO1.02MN/A1962
Ms. Onaiza Cadoret-Manier M.A., M.B.A., M.S.Exec. VP, Chief Global Product Strategy & Operations Officer930.82kN/A1965
Ms. B. Lynne Parshall Esq., J.D.Sr. Strategic Advisor & Director334.64kN/A1954
Dr. Richard S. Geary Ph.D.Exec. VP & Chief Devel. Officer946.26kN/A1958
Mr. Joseph T. Baroldi M.A., M.B.A., M.S.Exec. VP & Chief Bus. Officer815.87kN/A1979
Mr. Darren GonzalesChief Accounting Officer & Sr. VPN/AN/AN/A
Dr. C. Frank Bennett BSc, Ph.D.Exec. VP & Chief Scientific OfficerN/AN/A1957
Mr. D. Wade Walke Ph.D.Sr. VP of Investor RelationsN/AN/AN/A
Mr. Patrick R. O'Neil Esq.Exec. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec.N/AN/A1974
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.

Corporate Governance

Ionis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 1, 2023 is 4. The pillar scores are Audit: 8; Board: 3; Shareholder Rights: 5; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.